Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KIF5B | P33176 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15130833 | 0.82 | APLNR (0.56) | APLNRALDH1A1L3MBTL1DGAT1KDM1A | |
| SCHEMBL1249242 | 0.81 | APLNR (0.44) | APLNRALDH1A1L3MBTL1DGAT1KDM1A | |
| SCHEMBL8807188 | 0.79 | IDO1 (0.43) | APLNRALDH1A1SLC6A4NPC1RAB9A | |
| SCHEMBL31035431 | 0.79 | MAPK1 (0.41) | APLNRALDH1A1L3MBTL1NPC1LMNA | |
| SCHEMBL2550576 | 0.77 | APLNR (0.50) | APLNRDGAT1KDM1AKDM1BPYCR1 | |
| SCHEMBL30169618 | 0.77 | APLNR (0.50) | APLNRDGAT1KDM1AKDM1BPYCR1 | |
| SCHEMBL9515508 | 0.77 | APLNR (0.48) | APLNRALDH1A1L3MBTL1DGAT1NPC1 | |
| SCHEMBL1321414 | 0.76 | KDM4E (0.39) | APLNRPYCR1NPC1 | |
| SCHEMBL28056382 | 0.76 | CYP1A2 (0.42) | — | |
| SCHEMBL5041250 | 0.75 | ALDH1A1 (0.53) | APLNRALDH1A1L3MBTL1DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970116-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-8912219-B2 | Aryl sulfamide and sulfamate derivatives as RORc modulators | GENENTECH, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912219-B2 | Aryl sulfamide and sulfamate derivatives as RORc modulators | GENENTECH, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2794584-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014140059-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140059-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013092941-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092941-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | APLNR 3784/4885ALDH1A1 786/4885L3MBTL1 952/4885 |
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | RORA, RORC, RORB | APLNR 2108/4885ALDH1A1 1026/4885L3MBTL1 2925/4885 |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | RORA, RORC, RORB | APLNR 1509/4885ALDH1A1 684/4885L3MBTL1 4033/4885 |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | APLNR 861/4885ALDH1A1 997/4885L3MBTL1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.